Exciting New Treatment Updates Are on the Horizon for Advanced RCC
Moshe Ornstein, MD, highlights recent treatment updates for renal cell carcinoma.
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
VEN-HMA May Prolong Survival in Elderly Acute Myeloid Leukemia Population
A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.
NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC
Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.
AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care
Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.
FDA Approves Tarlatamab After Progression on Chemotherapy in ES-SCLC
The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
Dato-DXd Shows Improved Tolerability Vs Chemo in HR+/HER2– Breast Cancer
Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer.
Ovarian Cancer Linked to Genital Talcum Powder Use
Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis
Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
Liso-cel Earns FDA Accelerated Approval in R/R Follicular Lymphoma
Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.
Pre-Transplant FLT3-ITD Detection Confers Relapse/Death Risk in AML
Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.
FDA Grants Breakthrough Therapy Designation to Petosemtamab in HNSCC
Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.
FDA Approves HPV Self-Collection Solution for Cervical Cancer Detection
Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial
Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Higher Mortality Risk Reported in Cancer Surgery During COVID-19 Pandemic
Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
Investigators Discontinue Vibostolimab Combo in Resected Melanoma Trial
The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.
Complementary and Alternative Medicine in Cancer Care: Does It Have a Role?
While treatment centered around multiple drug options is common practice in oncology, the use of complementary and medicine alternative medicine is being introduced in the space.
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
Nivolumab ± Ipilimumab Yields Durable Responses in Cervical Cancer
The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
Nivolumab Combo Does Not Meet PFS End Point in Unresectable NSCLC
The progression-free survival end point was not met in the CheckMate -73L trial assessing patients with unresectable stage III non–small cell lung cancer.
Leveraging Surgical Oncology Advances in Colorectal Cancer Care
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.
Lifileucel Yields Responses in Metastatic Non–Small Cell Lung Cancer
Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
Nivolumab Meets ORR/PFS24 End Points in dMMR Uterine and Ovarian Cancer
Although the sample size for this trial was small, data still highlight a potential benefit with nivolumab in dMMR uterine and ovarian cancers.
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
Nivolumab Combo Shows Efficacy, Safety in Muscle-Invasive Bladder Cancer
Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.
![[SEBASTIAN KAULITZKI] - STOCK.ADOBE.COM](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F3fbe7b21eef28f23798900792090beea0407b955-950x1030.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "[SEBASTIAN KAULITZKI] - STOCK.ADOBE.COM")
